LCY-2-CHO has anti-inflammatory actions on macrophages. To understand its therapeutic implication in
atherosclerosis, we examined its effects on the expressions of anti-inflammatory and inflammatory
proteins in cultured rat aortic vascular smooth muscle cells (VSMC).
LCY-2-CHO is able to induce
heme oxygenase-1 (HO-1)
protein expression through a transcriptional action. The HO-1 inducting effect of
LCY-2-CHO was inhibited by
SB203580, N(G)-nitro-
l-arginine methylester (
l-NAME), and
wortmannin, but was not affected by
U0126 or
SP600125. In accordance
LCY-2-CHO increased
protein phosphorylation of p38, Akt, and eNOS. Nrf2 is a
transcription factor essential for HO-1 gene induction and we showed that
LCY-2-CHO is able to cause Nrf2 nuclear translocation and this action depends on p38, Akt and eNOS. In addition to induce anti-inflammatory HO-1,
LCY-2-CHO reduced
interleukin-1beta (IL-1beta)-induced inflammatory mediators,
inducible nitric oxide synthase (iNOS),
cyclooxygenase-2 (COX-2), growth-related
oncogene protein-alpha (GRO-alpha), and
interleukin-8 (IL-8). Inhibitory effect on IL-1beta-mediated
NF-kappaB activation was evidenced by the diminishment of
IkappaB kinase (IKK) phosphorylation and
IkappaBalpha degradation. In contrast, IL-1beta-mediated ERK and JNK activations were not changed by
LCY-2-CHO, while p38 activation by IL-1beta and
LCY-2-CHO displayed the non-additivity. Taken together, given the overall anti-inflammatory properties of
LCY-2-CHO in VSMC, in terms to induce HO-1 gene expression and inhibit inflammatory gene expression, these results highlight the therapeutic potential of
LCY-2-CHO in
atherosclerosis.